function

[Mirror] Quadratic Arithmetic Programs: from Zero to Hero

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/quadratic-arithmetic-programs-from-zero-to-hero-f6d558cea649 There has been a lot of interest lately in the technology behind zk-SNARKs, and people are increasingly trying to demystify something that many have come to call "moon math" due to its perceived sheer indecipherable complexity. zk-SNARKs are indeed quite challenging to grasp, especially due to the sheer number of moving parts that need to come together for the whole thing to work, but if we break the technology down piece by piece then

Blueberry Protocol Launches High-Leverage DeFi Hub Optimized For Liquidity Access and Risk Control

[PANAMA CITY, PANAMA] January 23, 2024 – Blueberry Protocol today announces the launch of its decentralized prime brokerage terminal, delivering industry-leading Loan-to-Value (LTV) ratios of up to 20x for optimized on-chain trading and yield strategies. Blueberry is the first protocol to enable decentralized access to generalized leverage models with leverage on Ethereum and offers an increasing value opportunity with more sophisticated security management and higher leverage than traditional prime brokerage. By merging innovative and transparent risk management instruments with an advanced leverage architecture, Blueberry aims to broaden accessibility, increase efficiency,

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

My Life As A Science Experiment ; Continues

  A year ago Every=Ten of Ten doctors told me with confidence that I would Not get better and could not survive with Kidney function of 4.1% and Creatinine of 12.32. Immediate dialysis leading to a hopeful transplant or; death. I rejected every doctors advice and had this idea that for as long as I can I would reverse engineer manually all the vital functions that kidneys influence. It's 13 months later and I function well using frequent blood tests to tweak my protocol. It's a 24/7 job with 20+

My Health Manifesto : Cracking The Code : Flying Solo

  Today when I Google "how long can a person live with my GFR 5% / kidney function the answer was "a few hours to a few weeks without dialysis." In a study with 8000+ patients 65+ with similar numbers; a month was the survival time. @68 (Stage 5 kidney failure is less than 15% /GFR; I'm not even anywhere on/near the chart) As I enter my Fourteenth/14th month; I am Defiantly hopeful. positive and optimistic that My Miracle will continue. #notmytimetodie #superoutlier While I challenge this death sentence I feel better and

Welcome Renal Warriors

I am a 68 year old man born in Brooklyn, New York and living for decades in Ithaca, NY. I also have 10 years each with homes in @San Ramon, Costa Rica and @Austin, Texas. My present and future dreams are in #Africa and I am setting up a base in @CapeTown, South Africa. #notmytimetodie #supportmymiracle #childofimmigrants #latebloomer. I was told a year ago that I would certainly die if I did not have not follow the standard treatment of care. I rejected both dialysis and a transplant and am

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Stablecoins Under Scrutiny

Amidst the market’s recovery from the recent onslaught of SEC crackdowns, rumors swirl over the potential targeting of stablecoins in their crosshairs. Such a move could have profound implications for cryptocurrency prices, making it crucial to gauge the likelihood of this scenario and the approach regulators might adopt. The largest stablecoins by market cap are Tether’s USDT and Circle’s USDC. Both are pegged to the US dollar and backed by various assets, typically highly liquid instruments like US Treasury bills. In theory, when someone wants to buy stablecoins from an